Rhythm Pharmaceuticals, Inc. — CureCurrent

How to interpret these research links

Connected source records

The exact organization name Rhythm Pharmaceuticals, Inc. appears in 31 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials31

Recruiting shown3

Roles2

SourceClinicalTrials.gov

Clinical trials

31 shown

A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756)NCT06760546 · lead sponsor · 2025-09-23

A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway ImpairmentNCT06239116 · lead sponsor · 2024-03-05

A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO)NCT07156578 · lead sponsor · 2025-11-10

ENROLLING_BY_INVITATION

A Study of Setmelanotide in Patients With Prader-Willi SyndromeNCT06772597 · lead sponsor · 2025-03-04

ACTIVE_NOT_RECRUITING

Open-Label Extension Study of SetmelanotideNCT06596135 · lead sponsor · 2024-10-21

A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic ObesityNCT06046443 · lead sponsor · 2024-07-11

A Trial of Setmelanotide in Acquired Hypothalamic ObesityNCT05774756 · lead sponsor · 2023-04-26

ACTIVE_NOT_RECRUITING

Setmelanotide in Pediatric Participants With Rare Genetic Diseases of ObesityNCT04966741 · lead sponsor · 2022-03-08

Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the MC4R PathwayNCT05194124 · lead sponsor · 2021-12-21

EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R PathwayNCT05093634 · lead sponsor · 2021-12-10

DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) PathwayNCT04963231 · lead sponsor · 2021-11-30

Open-Label Study of Setmelanotide in Hypothalamic ObesityNCT04725240 · lead sponsor · 2021-06-07

An Observational,Prospective Natural History Study of Early-Onset Extreme Obesity Due to Bi-Allelic Loss-of-Function Mutations in the POMC, PCSK1 or LEPR GenesNCT03621007 · lead sponsor · 2019-08-06

Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syndrome (AS) Participants With Moderate to Severe ObesityNCT03746522 · lead sponsor · 2018-11-23

Long Term Extension Trial of SetmelanotideNCT03651765 · lead sponsor · 2018-07-15

The TEMPO (Tracing the Effect of the MC4 Pathway in Obesity) RegistryNCT03479437 · lead sponsor · 2018-04-15

Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency ObesityNCT03287960 · lead sponsor · 2018-01-30

Setmelanotide in a Single Patient With Partial LipodystrophyNCT03262610 · lead sponsor · 2017-08-15

Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency ObesityNCT02896192 · lead sponsor · 2017-02-14

Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of ObesityNCT03013543 · lead sponsor · 2017-02-10

Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult VolunteersNCT02849977 · lead sponsor · 2016-09-28

Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Willi SyndromeNCT02311673 · lead sponsor · 2015-03-19

Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese PatientsNCT02041195 · lead sponsor · 2014-01-01

Effects of RM-493 on Energy Expenditure in Obese IndividualsNCT01867437 · lead sponsor · 2013-05-01

Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese ParticipantsNCT01749137 · lead sponsor · 2013-01-14

Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RM-493 Administered to Healthy, Obese, Non-diabetic VolunteersNCT02431442 · lead sponsor · 2012-01-01

An Expanded Access Protocol for Setmelanotide for Treatment of Bardet-Biedl Syndrome (BBS)NCT05183802 · lead sponsor

APPROVED_FOR_MARKETING

Real-World Effects of MC4R Agonist Therapy in BBS and Severe Genetic ObesityNCT07674290 · collaborator · 2023-01-01

INDIcators for Clarifying the bAckground of exTreme Obesity in childRenNCT06420622 · collaborator · 2024-04-15

Early Genetic Identification of ObesityNCT06239064 · collaborator · 2024-01-24

ACTIVE_NOT_RECRUITING

Melanocortin 4 Receptor Mutations and Obesity-associated DiseasesNCT01849705 · collaborator · 2012-10-01

Drugs studied in this sponsor's trials

2 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Rhythm Pharmaceuticals, Inc. as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.

setmelanotide18

placebo13

setmelanotide RxCUI 2469247 · Lead sponsor in 17 linked trial(s) · 2 currently recruiting 18 trials placebo RxCUI 8375 · Lead sponsor in 13 linked trial(s) · 1 currently recruiting 13 trials

Sponsor roles

lead sponsor27

collaborator4

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.